Cannabimimetic Properties of Ajulemic Acid

  title={Cannabimimetic Properties of Ajulemic Acid},
  author={Robert Edward Vann and Charles D. Cook and Billy R. Martin and Jenny L. Wiley},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={678 - 686}
  • R. VannC. Cook J. Wiley
  • Published 1 February 2007
  • Biology
  • Journal of Pharmacology and Experimental Therapeutics
Side effects of marijuana-based drugs and synthetic analogs of Δ9-tetrahydrocannabinol (Δ9-THC), including sedation and dysphoria, have limited their therapeutic application. Ajulemic acid (AJA), a side-chain synthetic analog of Δ8-THC-11-oic acid, has been reported to have anti-inflammatory properties without producing undesired psychoactive effects. Moreover, it has been suggested that AJA does not interact with cannabinoid receptors to produce its pharmacological effects. The aim of the… 

Figures and Tables from this paper

Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective

An overview of the endocannabinoid system, its components and functions and the current approaches to avoiding cannabimimetic side effects by separating them from the therapeutic effects are explained.

Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats

Rimonabant induces a discriminative stimulus in DTA that continues to show potential for further examination of cannabinoid receptor antagonism and resulted in strong unconditioned effects.

The cannabinoid acids, analogs and endogenous counterparts.

  • S. Burstein
  • Chemistry, Biology
    Bioorganic & medicinal chemistry
  • 2014

The Future of Cannabinoids as Analgesic Agents: A Pharmacologic, Pharmacokinetic, and Pharmacodynamic Overview

Cannabinoid receptor agonists and/or molecules that affect the modulation of endocannabinoid synthesis, metabolism, and transport may, in the future, offer extremely valuable tools for the treatment of a number of currently intractable disorders.

Discriminative stimulus properties of Δ 9 -Tetrahydrocannabinol (THC) in C57BL/6J mice

These studies demonstrate THC's ability to produce discriminative stimulus effects as well as demonstrate its pharmacological specificity and mechanism of action in a two-lever drug discrimination mouse model.

Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice.



Cannabis Discrimination of “Internal Bliss”?

  • J. Wiley
  • Biology
    Pharmacology Biochemistry and Behavior
  • 1999

Analgesic effects of 1',1' dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice.

Data is presented further characterizing the analgesic properties of the title substance which is a potent synthetic member of this group of cannabinoids and the formalin effect, which showed a typical two phase, time related, response.

Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities.

In agreement with earlier reports on the naturally occurring pentyl side chain acids, the synthetic acids showed little activity in producing catalepsy in the mouse, suggesting that they would be nonpsychotropic in humans.

Cannabinoids and pain responses: a possible role for prostaglandins

The evidence presented is consistent with a mechanism in which the metabolite inhibits eicosanoid synthesis whereas the parent drug elevates tissue levels of prostaglandins.

Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain

Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.

The goals of the studies described herein were to determine whether these bicyclic analogs possess similar pharmacological properties of delta 9-THC, to compare pharmacological activity after s.c. and i.v. administration, and to evaluate the structure-activity relationship of this series of analogs for further insight into cannabinoid mechanism of action.

Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.

In this preliminary study, CT-3 was effective in reducing chronic neuropathic pain compared with placebo and no major adverse effects were observed.

Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat